Oppenheimer reiterated coverage on Seres Therapeutics with a new price target

7/23/21 7:59:02 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Oppenheimer reiterated coverage of Seres Therapeutics with a rating of Outperform and set a new price target of $18.00 from $36.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MCRB

Date	Price Target	Rating	Analyst
5/8/2025	$6.00	Buy → Neutral	Chardan Capital Markets
10/24/2024		Neutral → Underweight	JP Morgan
6/26/2023	$12.00	Outperform	Oppenheimer
4/21/2023	$7.00	Neutral	JP Morgan
7/23/2021	$42.00 → $29.00	Buy	Canaccord Genuity
7/23/2021	$30.00 → $16.00	Buy	Chardan Capital
7/23/2021	$36.00 → $18.00	Outperform	Oppenheimer
7/23/2021	$46.00 → $25.00	Buy	HC Wainwright & Co.